TD Cowen analyst Tyler Van Buren initiates coverage on Maze Therapeutics (NASDAQ: MAZE) with a Buy rating.The analyst comments "MZE829 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE